Amplify Weight Loss Drug & Treatment ETF (NY:THNR)

24.70 UNCHANGED

Delayed Quote Updated: 8:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amplify Weight Loss Drug & Treatment ETF

3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗

April 17, 2026

Via MarketBeat

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Via Stocktwits

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗

February 04, 2026

Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is...

Via Stocktwits

Topics Intellectual Property

LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗

February 04, 2026

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Via Stocktwits

Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill ↗

December 23, 2025

Via Stocktwits

The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In ↗

December 09, 2025

Via Stocktwits

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗

January 30, 2026

Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.

Via Stocktwits

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗

September 18, 2025

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Via Benzinga

Topics ETFs

Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares ↗

December 13, 2024

Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase.

Via Benzinga

Topics ETFs

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗

July 18, 2024

Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.

Via Benzinga

ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential ↗

June 07, 2024

New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.

Via Benzinga

Topics ETFs

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.